22 Jan Astellas Pharma
Ha Tran, M.D., Medical Head, Biopharma and Ophthalmology
April 16 | 2:45pm | Salone dei Cavalieri, Section 2
Tokyo, Japan
(OTCMKTS: ALPMY)
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. This includes our focus on delivering breakthrough gene therapies with life-changing potential for patients across many disease areas. We are building one of the world’s most robust pipelines of gene therapies for genetic disorders and an end-to-end gene therapy infrastructure with industry-leading discovery, development, manufacturing and commercial capabilities. We have two candidates in clinical development for rare neuromuscular diseases: AT845, in Phase 1/2 for Pompe disease, and AT132 for X-linked myotubular myopathy, currently on clinical hold. Alongside our partners, clinicians, regulatory authorities and patient communities, we strive to overcome complex challenges across the value chain so we can deliver the promise of ground-breaking science to patients.
